Patients with COVID-19 Interstitial Pneumonia Exhibit Pancreatic Hyperenzymemia and Not Acute Pancreatitis

Raffaele Pezzilli
Department of Gastroenterology, San Carlo Hospital

Stefano Centanni
Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di Milano

Michele Mondoni
Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital

Rocco F. Rinaldo
Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di Milano

Matteo Davi
Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital

Rossana Stefanelli
Laboratory of Clinical Chemistry, ASST Santi Paolo e Carlo, San Paolo Hospital

GianVico Melzi d’Eril
Università degli Studi di Milano

Alessandra Barassi (✉ alessandra.barassi@unimi.it)
Laboratory of Clinical Chemistry, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di Milano

Research Article

Keywords: Amylase, Lipase, Clinical medicine, COVID-19, Acute pancreatitis

DOI: https://doi.org/10.21203/rs.3.rs-50275/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background and aims: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement is under debate. The aim of the study is to evaluate the presence of acute pancreatitis in COVID-19 patients and to assess the frequency of pancreatic hyperenzymemia.

Methods: From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males, 41 females; mean age 63.0 years, range 24-93 years) met these criteria and were enrolled in the study. The clinical data and serum activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits.

Results: None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis. However, it was found that 24.5% of the patients had amylase values above 53 IU/L and 16.4% had lipase values above 300 IU/L. Only one patient (0.9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis.

Conclusions: The presence of pancreatic hyperenzymemia in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

Introduction

Gastrointestinal manifestations of COVID–19 have been well established [3]; COVID–19 also involves the liver [4]. Acute pancreatic involvement in patients with COVID–19 has recently been reported; acute pancreatitis was defined on the basis of an elevation of serum pancreatic enzymes [5]. Confirmed cases of acute pancreatitis in COVID–19 patients have been anecdotally reported in two of three family members with the remaining one having only hyperamylasemia [6]. The present study was undertaken to assess the frequency of acute pancreatitis in consecutive patients affected by COVID–19.

Methods

The study was carried out in the Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy and it was approved by local Ethical Committee Milano Area 1 (n. 2020/ST/057) with a priori patient or appropriate proxy consent obtained prior to the participants’ entry into the study which was then carried out in accordance with the Helsinki Declaration of the World Medical Association.

Acute pancreatitis was defined as the presence of prolonged typical pancreatic pain associated with the findings of pancreatic abnormalities at imaging techniques and a three-fold increase in serum amylase and lipase activity [7].

Our patients did not required orotracheal intubation and sedation as those in Intensive Care Unit that are severely ill [8] because we had previously demonstrated that serum pancreatic enzymes could be elevated in those patients [9].
Organization (WHO) interim guidelines [10] plus chest computed tomography demonstrating lung involvement. Both genders were included.

Serum samples were obtained from all subjects at their initial observation; they were kept frozen at −20°C until analysis.

Patients

From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males, 41 females; mean age 63.0 years, range 24–93 years) met these criteria and were enrolled in the study.

The average time from the onset of respiratory symptoms to the blood samples was 22.2 days (range 0–47).

Novel Coronavirus (SARS-CoV–2) antibodies (Immunoglobulin [Ig] M/IgG) were also evaluated using the commercially available kit BioMedomics IgM-IgG Combined Antibody Rapid Test (Morrisville NC, USA). It is one of the world's first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus. The test has been used widely by the Chinese Center for Disease Control to combat COVID–19 infections and is now being made available globally. This newly developed test kit, the IgG-IgM combined antibody test kit, has a sensitivity of 88.66% and a specificity of 90.63% [11].

Based on the results of this assay, 12 patients (11.0%) were negative for IgM, 17 (15.6%) were weakly positive and the remaining 80 (73.4%) were positive at high title; regarding IgG, 13 patients (1.8%) were negative, one was weakly positive (0.9%) and 96 (87.3%) were positive at high title.

All patients were treated according to current therapeutic modalities [12]; regarding ventilation support, seven patients (6.4%) did not receive any ventilator support, 42 (38.2%) received oxygen via nasal cannula, oxygen mask or an oxygen mask with a reservoir, 41 (37.3%) were on a continuous positive airway pressure device (CPAP) and 20 (18.2%) on non-invasive mechanical ventilation (NIMV).

Six patients (5.5%) were followed by a home care team, 42 (38.2%) were discharged in good general health, 53 (48.2%) are still in hospital on May 3rd 2020, and 9 (8.2%) died from COVID–19. None of the patients experienced abdominal pain, 14 (12.7%) had diarrhea, and three (2.7%) had nausea/vomiting; only one patient experienced both nausea/vomiting and diarrhea.

All authors had access to the study data and reviewed and approved the final manuscript.

Serum assays

Serum pancreatic amylase and serum lipase were assayed using commercially available kits. Pancreatic amylase was assayed using pancreatic isoamylase (Sentinel Ch. S.p.A., Milan, Italy). The linearity of the method was 4.0 to 2000 U/L; within-run coefficient of variation (CV) was 0.3 to 0.7% and total imprecision CV was 3.0 to 5.7%. The upper reference limit (URL) of pancreatic amylase was 53 U/L. Lipase was assayed using VITROS Chemistry Products LIPA Slides (Ortho-Clinical Diagnostics, High Wycombe, United Kingdom). The URL of lipase was 300 U/L. The linearity of the method was 10 to 2000 U/L; within-run CV was 1.1 to 6.1% and total imprecision CV was 1.8 to 12.2%.

Total bilirubin (upper reference value equal to 1.30 mg/dL), direct bilirubin (upper reference value equal to 0.3 mg/dL), alanine aminotrasferase (ALT) (upper reference value equal to 35 U/L), aspartate aminotransferase (AST) (upper reference value equal to 36 U/L), gamma-GT (GGT) (upper reference value equal to 58 U/L) and C-reactive protein (CRP) (upper reference value equal to 10 mg/L) were assayed using commercially available kits (Ortho-Clinical Diagnostics, High Wycombe, United Kingdom).
Statistical analysis

No statistical sample size calculation was carried out a priori, and the sample size was equal to the number of patients treated during the study period. Data were reported as mean values ± standard deviations for the continuous variables and as absolute number and percentage for the categorical variables. The Kolmogorov-Smirnov test was used to evaluate the normal distribution of the blood parameters. Statistical analyses were carried out using the Mann-Whitney U-test, the Spearman rank correlation and the chi squared test. The statistical analyses were carried out by running the SPSS/PC+ statistical package (SPSS Inc., ver. 23.0 Chicago, IL, USA) on a personal computer. Two-tailed P values less than 0.05 were considered to be statistically significant.

Results

There were no differences in age between male (62.1±15.2 years) and female (64.4±15.3) patients at the onset of COVID–19 (P = 0.627).

The values of amylase, lipase, total bilirubin, direct bilirubin, ALT, AST, GGT and CRP were not normally distributed even after log transformation, and their values in the 110 patients studied are reported in Table 1. The correlations among the various serum assays are reported in Table 2.

None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis according to the criteria used in this study for the definition of the disease. However, it was found that 27 patients (24.5%) had amylase values above 53 IU/L and 18 (16.4%) had lipase values above 300 IU/L (Figure 1a e 1b). Only one patient (0.9%) had values of both amylase and lipase in excess of three-fold the upper normal limit.

Elevated serum amylase levels were not related to the interval from the day of onset of the COVID–19 and the day of blood sample (correlation coefficient 0.106, P = 0.279) whereas there was a positive correlation regarding lipase (correlation coefficient 0.264, P = 0.006).

There were no relationships when taking into consideration amylase and lipase (normal values and high values), and the three classes of IgM and IgG values (negative, weakly positive, positive at high titre) (data not shown for brevity).

There were no statistically significant difference in amylase and lipase serum activities in patients having nausea/vomiting (amylase: 32.1±18.7 IU/L, P = 0.438; lipase: 80.7±42.4 IU/L, P = 0.134) and in those who did not (amylase: 46.3±35.7 IU/L; lipase: 200.3±240.0 IU/L), or in patients having diarrhea (amylase: 65.4±64.2 IU/L, P = 0.198; lipase: 303.0±544.4 IU/L, P = 0.615) and in those who did not (amylase: 43.1±28.5 IU/L; lipase: 181.5±149.3 IU/L).

Regarding the oxygen support, a statistical difference was found in amylase serum activities among the various types of oxygen support used (amylase P = 0.047) whereas this difference was not found for lipase (P = 0.065) (Table 3).

Discussion

The gastrointestinal manifestation of COVID–19 patients is well known; this study found that 12.7% of patients had diarrhea and 2.7 % had nausea/vomiting; these figures are similar to those reported by Wang et al. [13]. Nausea, vomiting and abdominal discomfort may also appear during the course of the disease [14]. The reason why (SARS-CoV–2)-infected pneumonia may involve the gastrointestinal tract is probably due to the fact that the virus has been found more commonly in the saliva [15] but has also been found in the feces in 29% of patients [16]. However, more recently, it has been reported that SARS-CoV–2 infection may also cause acute pancreatic damage [17]. The Authors found, in a retrospective study, that 17% of patients experienced a pancreatic injury. This finding was supported only by the elevation of serum amylase and lipase. In addition, confirmed cases of acute pancreatitis in COVID–19 patients have been
anecdotally reported in two of three family members with the other one having only hyperamylasemia [6]. The present study was undertaken for this reason. Acute pancreatitis was defined according to accepted International criteria [7] and the Authors found that none of their patients had an episode of acute pancreatitis as defined by the presence of persistent abdominal pain associated with a 5-fold increase in serum pancreatic enzymes, and imaging showing acute alterations of the pancreatic gland. On the contrary, the Authors found that COVID–19 patients could have an increase in serum pancreatic enzymes, such as amylase (24.5% of the cases) and lipase (16.4% of the cases), and only one had a three-fold increase in this enzyme without pain and alteration of the pancreatic gland at imaging. The elevations of the serum pancreatic enzymes were not related to either the presence of diarrhea or nausea/vomiting, or to the IgM and IgG status. Why this happened requires additional studies. similarly to COVID–19, the presence of pancreatic hyperenzymemia in other viral diseases has been reported; the Authors found that, in 78 patients with chronic liver diseases due to hepatitis C virus (HCV) or hepatitis b virus (HBV) infection, the serum amylase levels were abnormally elevated in 27 patients (35%; 22 liver cirrhosis, 5 chronic active hepatitis) whereas the serum lipase levels were elevated in only 16 patients (21%; 15 liver cirrhosis, 1 chronic active hepatitis) [18]; this also happens in mumps and HIV [19, 20]. Pancreatic hyperenzymemia in these patients could result from various causes; pancreatic cells highly express angiotensin converting enzyme 2, the transmembrane protein required for SARS-CoV–2 entry [21], and the pancreatic renin-angiotensin system plays important endocrine and exocrine roles in hormone secretion [22] which could be the effect of drugs used for antiviral therapy. Even if no studies regarding the pancreas of COVID–19 patients have been found, a recent pathological report from China found that, even if the damage was located predominantly in the lungs, there were slight alterations in the pancreas, mainly represented by degeneration of some islet cells [23]. The data in the present study regarding liver function tests confirmed those previously reported [24] and the Authors suggest that, in patients with elevated liver function tests who have suspected or known COVID–19, it is necessary to also consider alternative etiologies. In hospitalized patients, it is also useful to obtain these tests at the time of admission and throughout the hospitalization, particularly in the context of COVID–19 drug treatment.

Finally, this study used a new test for evaluating the immunological response to novel coronavirus infection. It was found that this assay, considering only strong positivity for the two classes of immunoglobulins, had a sensitivity of 73.4% for IgM and 87.3% for IgG. These preliminary data are interesting but should be confirmed by studies involving a larger number of patients.

In conclusion, during COVID–19, serum amylase is more frequently elevated than serum lipase, but none of the patients with pancreatic hyperenzymemia showed acute clinical pancreatic injury. The presence of pancreatic hyperenzymemia in a patient with COVID–19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

Declarations
Funding:
None

Conflicts of interest:
the authors disclose no conflicts

Author Contributions:
Acquisition, analysis and interpretation of data: Centanni S, Barassi A, Mondoni M, Rinaldo RF, Davì M, Stefanelli R. Drafting of the manuscript: Pezzilli R and Barassi A. Critical revision of the manuscript for important intellectual content: Centanni S, Barassi A, Pezzilli R, Melzi d’Eril GV. Statistical analysis: Pezzilli R

Competing interest:

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020 Jan 30. doi: 10.1001/jama.2020.1097.

2. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.

3. Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020 May;115(5):766-773.

4. Zhao XY, Xu XX, Yin HS, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20(1):311.

5. Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. pii: S0016-5085(20)30409-1. doi: 10.1053/j.gastro.2020.03.055.

6. Hadi A, Werge MP, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members, Pancreatology. 2020 May 5. doi.org/10.1016/j.pan.2020.04.021.

7. Banks PA, Bollen TL, Dervenis C, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62(1):102-11.

8. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020 Apr 6. doi: 10.1001/jama.2020.5394.

9. Pezzilli R, Barassi A, Imbrogno A, et al. Is the pancreas affected in patients with septic shock? A prospective study. Hepatobiliary Pancreat Dis Int 2011;10(2):191-5.

10. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020.

11. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25727.

12. SIMIT Società Italiana di MalattieInfettive e Tropicali, Sezione Regione Lombardia. Linee guida sulla gestione terapeutica e di supporto per pazienti con infezione da coronavirus COVID-19. https://www.omceoch.it/storage/attachments/Ebka.COVID19%20linee%20guida%20trattamento%2001MAR.pdf.pdf.

13. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585.

14. Holshue ML, DeBolt C, Lindquist S, et al. Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382(10):929-936.

15. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020 Feb 12. doi: 10.1093/cid/ciaa149.

16. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 Mar 11. doi: 10.1001/jama.2020.3786.
17. Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055.

18. Pezzilli R, Andreone P, Morselli-Labate AM, et al. Serum pancreatic enzyme concentrations in chronic viral liver diseases. Dig Dis Sci 1999;44(2):350-5.

19. Havličková M, Limberková R, Smišková D, et al. Mumps in the Czech Republic in 2013: Clinical Characteristics, Mumps Virus Genotyping, and Epidemiological Links. Cent Eur J Public Health 2016;24(1):22-8.

20. Pezzilli R, Gullo L, Ricchi E, et al. Serum pancreatic enzymes in HIV-seropositive patients. Dig Dis Sci 1992;37(2):286-8.

21. Liu FL, Zou X, Fang W, Wu M, et al. Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection. Am J Physiol Endocrinol Metab. 2020 March 3; doi:/10.1101/2020.02.28.20029181.

22. Fang HJ, Yang JK. Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. J Int Med Res. 2010;38(2):558-569.

23. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020; doi: 10.3760/cma.j.cn112151-20200312-00193

24. Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. May 4, 2020 doi: 10.1053/j.gastro.2020.03.072.

### Tables

**Table 1.** Values of the various biochemical assays in the 110 patients studied. Results are reported as mean, standard deviation (SD) and range.

| Assay                        | URL | Mean value±SD | Range         |
|------------------------------|-----|---------------|---------------|
| Pancreatic amylase (IU/L)    | 53  | 45.9±35.34    | 4.9-265.6     |
| Lipase (IU/L)                | 300 | 197.0±237.5   | 12.0-2175.0   |
| Total bilirubin (mg/dL)      | 1.30| 0.40±0.28     | 0.10-1.50     |
| Direct bilirubin (mg/dL)     | 0.50| 0.72±0.14     | 0.01-0.13     |
| ALT (IU/L)                   | 35  | 35.5±33.4     | 4.0-256.0     |
| AST (IU/L)                   | 36  | 35.3±17.3     | 12.0-106.0    |
| Gamma-GT (IU/L)              | 58  | 90.2±101.2    | 13.0-558.0    |
| C-reactive protein (mg/L)    | 10  | 35.2±41.0     | 5.0-151.2     |

Abbreviations. URL: upper reference limit; ALT: alanine aminotransferase; AST: aspartate aminotransferase

**Table 2.** Correlation coefficient and the respective P values of the various biochemical assays in the 110 patients studied. Significant relationships are reported in bold.
| Correlation coefficient | Lipase | Amylase | Total bilirubin | Direct bilirubin | ALT | AST | GGT | CRP |
|-------------------------|--------|---------|-----------------|-----------------|-----|-----|-----|-----|
| Lipase                  | 0.708  | 0.061   | 0.044           | 0.138           | -0.039 | 0.212 | -0.115 |
| P value                 | <0.001 | 0.525   | 0.647           | 0.151           | 0.685 | 0.026 | 0.23 |
| Amylase                 | 0.708  | 0.145   | 0.095           | 0.244           | 0.024 | 0.312 | -0.111 |
| P value                 | <0.001 | 0.13    | 0.326           | **0.01**        | 0.806 | **0.001** | 0.247 |

Abbreviations. ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT gamma-glutamyl transpeptidase; CRP: C-reactive protein

Table 3. Amylase and lipase serum activities in patients with different O\textsubscript{2} support.

| Amylase (IU/L) | No.of patients | Mean±SD | Range         | P value |
|----------------|----------------|---------|---------------|---------|
| None O\textsubscript{2} support | 7 | 31.9±20.1 | 6.6-70.9 | 0.046 |
| Ventimask | 42 | 36.3±25.0 | 4.9-161.3 | |
| CPAP | 41 | 56.1±45.7 | 8.9-265.6 | |
| NIMV | 20 | 50.0±28.3 | 19.3-113.8 | |
| Total | 110 | 45.9±35.4 | 4.9-265.6 | |

| Lipase (IU/L) | No.of patients | Mean±SD | Range         | P value |
|----------------|----------------|---------|---------------|---------|
| None O\textsubscript{2} support | 7 | 119.9±69.3 | 12.0-205.0 | 0.065 |
| Ventimask | 42 | 131.7±82.7 | 16.0-433.0 | |
| CPAP | 41 | 258.1±348.8 | 24.0-2175.0 | |
| NIMV | 20 | 236.0±173.1 | 23.0-646.0 | |
| Total | 110 | 197.0±237.5 | 12.0-2175.0 | |

Abbreviations. CPAP: continuous positive airway pressure; NIMV: non-invasive mechanical ventilation

Figures
Figure 1

Figure 1. Individual serum activities of pancreatic amylase (a) and lipase (b) in 110 patients having COVID-19. The horizontal dotted lines indicate the upper reference limit of each enzyme.